Abstract
The value of coagulation factor V and VIII/V levels as prognostic indicators was assessed in 27 patients with fulminant hepatic failure and compared with other predictive indices. Admission factor V levels were significantly reduced in 22 patients with paracetamol induced hepatic failure compared with a healthy control group (median 9.5% v 103%, respectively; p less than 0.001) and with lower values in non-A non-B hepatitis (median 2.7%). Values in the seven patients who died after paracetamol overdose, considered together with the four who underwent liver transplantation (group median 5.1%), were significantly lower than in the 11 who survived (median 11.8%; p less than 0.01). Median admission factor VIII was higher in those who died or received a transplant than in those who survived (298% v 162%; p less than 0.05), with both results higher than in healthy volunteers (median 104%; p less than 0.01) but lower than in non-A non-B hepatitis (median 340%). The ratio of factor VIII/V on admission was less than 30 in all patients who survived paracetamol overdose (median 17) with corresponding values greater than 30 in 10 of 11 of those who died (median 39). A factor V result less than or equal to 10% on admission predicted an adverse outcome in 10 of 11 fatal cases, a 91% sensitivity which was greater than for the previously defined indicator of an arterial blood pH less than 7.30 on admission (sensitivity 82%). Prothrombin time at admission or on day 4 did not usefully predict outcome in our series. Predictive accuracy was 73% and 82% for factor V and admission acidosis respectively and 95% for factor V in conjunction with admission coma grade III or IV and factor VIII (ratio > 30). These criteria may be useful in selecting patients with paracetamol induced fulminant hepatic failure for transplantation.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baele G., Matthijs E., Barbier F. Antihaemophilic factor A activity, F VIII-related antigen and von Wilebrand factor in hepatic cirrhosis. Acta Haematol. 1977;57(5):290–297. doi: 10.1159/000207893. [DOI] [PubMed] [Google Scholar]
- Bernuau J., Goudeau A., Poynard T., Dubois F., Lesage G., Yvonnet B., Degott C., Bezeaud A., Rueff B., Benhamou J. P. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986 Jul-Aug;6(4):648–651. doi: 10.1002/hep.1840060417. [DOI] [PubMed] [Google Scholar]
- Bismuth H., Samuel D., Gugenheim J., Castaing D., Bernuau J., Rueff B., Benhamou J. P. Emergency liver transplantation for fulminant hepatitis. Ann Intern Med. 1987 Sep;107(3):337–341. doi: 10.7326/0003-4819-107-2-337. [DOI] [PubMed] [Google Scholar]
- Davis M. Protective agents for acetaminophen overdose. Semin Liver Dis. 1986 May;6(2):138–147. doi: 10.1055/s-2008-1040597. [DOI] [PubMed] [Google Scholar]
- Francavilla A., Makowka L., Polimeno L., Barone M., Demetris J., Prelich J., Van Thiel D. H., Starzl T. E. A dog model for acetaminophen-induced fulminant hepatic failure. Gastroenterology. 1989 Feb;96(2 Pt 1):470–478. doi: 10.1016/0016-5085(89)91573-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gazzard B. G., Henderson J. M., Williams R. Factor VII levels as a guide to prognosis in fulminant hepatic failure. Gut. 1976 Jul;17(7):489–491. doi: 10.1136/gut.17.7.489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gimson A. E., White Y. S., Eddleston A. L., Williams R. Clinical and prognostic differences in fulminant hepatitis type A, B and non-A non-B. Gut. 1983 Dec;24(12):1194–1198. doi: 10.1136/gut.24.12.1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harrison P. M., Keays R., Bray G. P., Alexander G. J., Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990 Jun 30;335(8705):1572–1573. doi: 10.1016/0140-6736(90)91388-q. [DOI] [PubMed] [Google Scholar]
- Harrison P. M., O'Grady J. G., Keays R. T., Alexander G. J., Williams R. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ. 1990 Oct 27;301(6758):964–966. doi: 10.1136/bmj.301.6758.964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kelly D. A., O'Brien F. J., Hutton R. A., Tuddenham E. G., Summerfield J. A., Sherlock S. The effect of liver disease on factors V, VIII and protein C. Br J Haematol. 1985 Nov;61(3):541–548. doi: 10.1111/j.1365-2141.1985.tb02859.x. [DOI] [PubMed] [Google Scholar]
- Langley P. G., Hughes R. D., Williams R. Increased factor VIII complex in fulminant hepatic failure. Thromb Haemost. 1985 Oct 30;54(3):693–696. [PubMed] [Google Scholar]
- Langley P. G., Williams R. The effect of fulminant hepatic failure on protein C antigen and activity. Thromb Haemost. 1988 Apr 8;59(2):316–318. [PubMed] [Google Scholar]
- Mosvold J., Abildgaard U., Jenssen H., Andersen R. Low antithrombin III in acute hepatic failure at term. Scand J Haematol. 1982 Jul;29(1):48–50. doi: 10.1111/j.1600-0609.1982.tb00561.x. [DOI] [PubMed] [Google Scholar]
- O'Grady J. G., Alexander G. J., Hayllar K. M., Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989 Aug;97(2):439–445. doi: 10.1016/0016-5085(89)90081-4. [DOI] [PubMed] [Google Scholar]
- O'Grady J. G., Gimson A. E., O'Brien C. J., Pucknell A., Hughes R. D., Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology. 1988 May;94(5 Pt 1):1186–1192. doi: 10.1016/0016-5085(88)90011-x. [DOI] [PubMed] [Google Scholar]
- Peleman R. R., Gavaler J. S., Van Thiel D. H., Esquivel C., Gordon R., Iwatsuki S., Starzl T. E. Orthotopic liver transplantation for acute and subacute hepatic failure in adults. Hepatology. 1987 May-Jun;7(3):484–489. doi: 10.1002/hep.1840070312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tygstrup N., Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis. 1986 May;6(2):129–137. doi: 10.1055/s-2008-1040596. [DOI] [PubMed] [Google Scholar]